DDInter223 DDInter596
Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Bosentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Bosentan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Bosentan {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Bosentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Bosentan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Bosentan {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Bosentan {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) interacts with {v} (Gene) CDC37
CDC37 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Bosentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Bosentan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Bosentan {u} (Compound) binds {v} (Gene) EDNRB
EDNRB {u} (Gene) interacts with {v} (Gene) NOS3
NOS3 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) resembles Doxorubicin (Compound)
Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxorubicin (Compound)
Bosentan (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Doxorubicin (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) resembles Daunorubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Bosentan (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Epirubicin (Compound) and Epirubicin (Compound) resembles Doxorubicin (Compound)
Bosentan (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) interacts with CDC37 (Gene) and CDC37 (Gene) is upregulated by Doxorubicin (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)
Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with prostate cancer (Disease) and prostate cancer (Disease) is treated by Doxorubicin (Compound)
Bosentan (Compound) binds EDNRB (Gene) and EDNRB (Gene) interacts with NOS3 (Gene) and NOS3 (Gene) is bound by Doxorubicin (Compound)